Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cauterex is a topical analgesic cream developed and marketed by Megat Pharmaceutical in Ecuador. Its active ingredient is capsaicin (0.075%), derived from the dried extract of *Capsicum annuum* L. Capsaicin acts as a selective agonist for the transient receptor potential vanilloid 1 (TRPV1) receptor, which is primarily expressed on nociceptive nerve fibers. Initial application typically causes a localized burning sensation, but repeated use leads to the desensitization of sensory axons and the depletion of substance P, a neurotransmitter involved in pain signaling. Cauterex is indicated for the relief of various pain conditions, including neuropathic pain, muscle pain, and arthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cauterex.